Covid 19

Product Details:

Favizit tablet is used to treat mild-to-moderate COVID-19 disease in adults under restricted emergency use. Favizit tablet is an antiviral medicine containing favipiravir as its active ingredient. This medicine stops the replication of the virus. You should avoid using this medicine if you are pregnant, breastfeeding, suffering from liver or kidney problems or are allergic to it.

Additional Information:

• Production Capacity: 5000 box per day
• Delivery Time: 2-3 days after order
• Packaging Details: 10x10 Alu Alu

Product Details:

Fabiflu tablet is used to treat mild-to-moderate COVID-19 disease in adults under restricted emergency use. Fabiflu tablet is an antiviral medicine containing favipiravir as its active ingredient. This medicine stops the replication of the virus. You should avoid using this medicine if you are pregnant, breastfeeding, suffering from liver or kidney problems or are allergic to it.

Additional Information:

• Production Capacity: 1000 box per month
• Delivery Time: 2 to 3 days
• Packaging Details: 10x10 Alu Alu

Product Details:

Fabiflu tablet is used to treat mild-to-moderate COVID-19 disease in adults under restricted emergency use. Fabiflu tablet is an antiviral medicine containing favipiravir as its active ingredient. This medicine stops the replication of the virus. You should avoid using this medicine if you are pregnant, breastfeeding, suffering from liver or kidney problems or are allergic to it.

Additional Information:

• Production Capacity: 5000 box per day
• Delivery Time: within 3 days
• Packaging Details: 1x17 tablets

Product Details:

Enoxaparin is used in the treatment and prevention of Blood clots. It prevents the formation of blood clots in the legs, lungs, brain or heart.

How Enoxaparin works:
Enoxaparin is an anticoagulant. It works by inactivating certain blood-clotting proteins. This prevents the formation of blood clots and prevents blockages in the blood vessels of the body.

Common side effects of Enoxaparin
Anemia (low number of red blood cells), Bleeding

Note:

• Subcutaneous route
• Intravascular route during hemodialysis.
• Do not inject intravascular
• Low molecular weight heparin

Additional Information:

• Production Capacity: 1000000

Product Details:

Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication

Product Details:

• It is used for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF) in adults
• IPF is a condition in which the tissues in your lungs become swollen and scarred over time, and as a result makes it difficult to breathe deeply. This makes it hard for your lungs to work properly
• It helps to reduce scarring and swelling in the lungs, and helps you breathe better

Product Details:

Remdesivir is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir is an adenosine nucleotide prodrug that distributes into cells where it is metabolized to form the pharmacologically active nucleoside triphosphate metabolite. Metabolism of remdesivir to remdesivir triphosphate has been demonstrated in multiple cell types. Remdesivir triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. Remdesivir triphosphate is a weak inhibitor of mammalian DNA and RNA polymerases with low potential for mitochondrial toxicity.

Additional Information:

• Production Capacity: 500000

Product Details:

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
Safety controversyIn April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[3] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.
COVID-19In late July 2020 Merck, which had been partnering with Ridgeback Biotherapeutics on developing the drug, announced its intention to move molnupiravir to late stage trials beginning in September 2020. On October 19 2020, Merck began a one year Stage 2/3 trial focused on hospitalized patients.

Product Details:

Uses of Casirivimab and Imdevimab Injection:

• Treat mild to moderate COVID-19 infection

 

How Casirivimab and Imdevimab Injection works:

Casirivimab and Imdevimab are monoclonal antibodies that gets attached to the spike protein of SARS-CoV-2 and block its attachment and entry into human cells. 

 

Interaction with other drugs:

Inform your doctor about any medications you are taking or have taken before the treatment.

 

More Information:

Store in a refrigerator at 2-8°C and keep out of reach of children.